Corvus (CRVS) Q2 FY26 earnings call

Corvus Pharmaceuticals reported significant progress across its socalitinib pipeline, particularly in atopic dermatitis where Phase 1 data showed compelling efficacy and safety. The company is advancing its Phase 3 PTCL program and initiating new trials in hidradenitis suppurativa and asthma, leveraging its ITK inhibition mechanism. Financials reflect increased R&D investment and a strengthened cash position, providing runway into Q2 2028, despite an increased net loss.